Crohn’s and Colitis Canada’s MyGut App Receives Funding from TD Bank Group

TD Ready Commitment

Toronto, ON, April 17, 2023 – Crohn's and Colitis Canada has been awarded a $600,000 grant from TD Bank Group (TD) through the TD Ready Commitment, the Bank's corporate citizenship platform, to continue developing the MyGut app. Launched in 2019, the app allows those with Crohn’s and colitis to identify trends and actions to better manage these diseases. Promoting and increasing the number of users is another goal.

“There isn’t any other app that offers this level of support. Being able to track my symptoms and daily activities provides a better understanding of how I have been feeling and what a normal day looks like. I wish an app like this existed when I was diagnosed, as it would have helped me better manage my disease earlier,” said Jordan LoMonaco, a business intelligence analyst in Toronto who has lived with ulcerative colitis for six years. “MyGut” offers a range of educational resources, too. Whether you’re looking to learn about the disease as you’re newly diagnosed or have questions about specific topics, the app arms you with a wealth of knowledge.”

“How healthy we feel has a profound impact on our ability to participate in our communities, attend work, or plan for the future. Every case of Crohn’s and colitis is different and each person has their own experience and symptoms, which is why tracking and seeing trends is so important,” says Alicia Rose, Associate Vice President, Social Impact, TD Bank Group. “Through the TD Ready Commitment, we’re proud to support innovative solutions and technology like  Crohn’s and Colitis Canada's MyGut app that help enable effective treatment to improve the lives of people in Canada with chronic diseases.”

“We are thankful for the generosity of TD as we continue to invest in digital health technology to support those living with Crohn’s and colitis,” says Lori Radke, President and CEO, Crohn’s and Colitis Canada. “These diseases evolve over time, so being able to identify what is changing, what is working and what is not working can all contribute to better health outcomes.”

About the MyGut app

MyGut™ is a free, easy-to-use-app that enables people with Crohn’s disease or ulcerative colitis to track, understand, and manage their health journey. Available for iOS and Android, MyGut features a personalized dashboard with curated educational content based on a user’s unique needs and interests. The app creates an all-encompassing picture of a person’s journey with Crohn’s or colitis as they track symptoms and activities on a daily basis. The app also provides a means to capture and share information with healthcare providers, helping patients manage their health and wellness on a daily basis, between clinic appointments. To learn more about the MyGut app, visit crohnsandcolitis.ca/MyGut.

About Crohn’s and Colitis Canada

Crohn’s and Colitis Canada aspires to cure Crohn’s disease and ulcerative colitis and to improve the quality of life of everyone affected by these diseases. We are committed to fulfilling this in the work we do, guided by a set of values and the objectives laid out in our 2023-2026 Impact Strategy. We have a critical role as a contributor, and as a connector and collaborator with others in Canada and around the world who share this vision. Together, we are driving towards delivering a positive impact for everyone affected by inflammatory bowel disease (IBD). For more information, visit crohnsandcolitis.ca and follow us @getgutsycanada on Twitter, Facebook, and Instagram.
 

-30-


For more information, or to arrange an interview, please contact:

Paul Kilbertus
Senior Manager, Communications and PR
Crohn’s and Colitis Canada
(416) 920-5035
media@crohnsandcolitis.ca 

  • Canada has among the highest incidence rates of Crohn's and colitis in the world.
  • 1 in 140 Canadians lives with Crohn’s or colitis.
  • Families new to Canada are developing these diseases for the first time.
  • Incidence of Crohn’s in Canadian kids under 10 has doubled since 1995.
  • People are most commonly diagnosed before age 30.

Other Areas of Interest